A SNP in the intron of TLL1 gene, encoding a type of matrix metalloprotease that has relation to the liver development, was associated with HCC risk after SVR by interferon-based antiviral therapy in a Japanese cohort (adjusted hazard ratio (HR), 1.78), whereas this SNP was not associated with HCC risk after SVR by direct-acting antiviral (DAA) in a Caucasian cohort [84,85]. The gene discussed is TLL1; the disease is hepatocellular carcinoma.